In the first CVOT called Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME), SGLT2 inhibitors showed promising CV benefits [13]. Here, SLC5A2 is linked to diabetes mellitus.